With two approved drugs and close to 300 clinical / preclinical product candidates, the bispecific a
With two approved drugs and close to 300 clinical / preclinical product candidates, the bispecific antibody therapeutics pipeline has evolved significantly over the past few years, claims Roots Analysis With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications.
Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years. To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this link The USD 6.9 billion financial opportunity (by 2030) within the bispecific antibody therapeutics market has been analyzed across the following segments: The Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain: Table of Contents To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html Contact Details Gaurav Chaudhary +1 (415) 800 3415
[email protected] Source: Free Articles from ArticlesFactory.com Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years..